A multicenter open label Phase 2 study to evaluate the efficacy and saftey of Sutetnib maleate capsule in locally advanced or metastatic NSCLC

Brief description of study

This study is for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. The main goal is to see if a medicine called sutetinib (which may be able to stop or slow down the cancer from growing) can help these patients. The study team wants to check if the medicine has few side effects and how it works in the body. They'll do this study with two groups of patients, one with the gene changes from the start, and the other group who got them later. The study team is doing this because there are no good treatments for these patients right now, and earlier tests showed this medicine might help some of them. Patients will take the medicine for a few weeks, and doctors will watch to see if it helps with the cancer.


Clinical Study Identifier: s23-00227
ClinicalTrials.gov Identifier: NCT06010329
Principal Investigator: Elaine Shum.
Other Investigators: Samantha VanMaanen, Carol M Lee, Elka R Travis, Salman Rafi Punekar, Jessica Wang, Elise Roughan, Jonathan B Kahn, James Newman, Gabrielle Fridman, Joshua K Sabari, Marissa Rybstein, David Mendoza, Melissa L Martinez, Vamsidhar Velcheti, Jeffrey G Schneider, Sally Lau, Meina Fung, Kirby Rodriguez, Natalia Cherkassky.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.